Related Experiment Video
Updated: Mar 16, 2026
06:10
Following Cell-fate in E. coli After Infection by Phage Lambda
Published on: October 14, 2011
24.3K
Induction and Purification of C. difficile Phage Tail-Like Particles
John P Hegarty1, William Sangster2, Robert E Ashley3,4
1Department of Surgery, Division of Colorectal Surgery, The Pennsylvania State University College of Medicine, 500 University Drive, H-137, 850, Hershey, PA, 17033, USA. jhegarty1@hmc.psu.edu.
Methods in Molecular Biology (Clifton, N.J.)
|August 11, 2016
Summary
New methods enable the production of phage tail-like particles (PTLPs) to combat Clostridioides difficile infection (CDI). These PTLPs offer a promising alternative to traditional antibiotics for treating CDI.
Area of Science:
- Microbiology
- Bacteriophage research
- Infectious disease treatment
Background:
- Conventional antibiotics face limitations in treating Clostridioides difficile infection (CDI).
- Alternative therapeutic strategies for CDI are urgently needed.
- Bacteriophages and R-type bacteriocins (phage tail-like particles or PTLPs) show potential against CDI.
Purpose of the Study:
- To describe optimized methods for the induction and purification of C. difficile PTLPs.
- To enable the production of concentrated, non-contractile, and non-aggregated PTLP samples.
- To facilitate sensitivity testing and structural electron microscopy studies of C. difficile PTLPs.
Main Methods:
- Induction of C. difficile PTLPs.
- Purification of PTLPs.
- Optimization of production methods for concentrated, non-aggregated samples.
Main Results:
- Successful induction and purification of C. difficile PTLPs were achieved.
- Methods allow for the production of concentrated, non-contractile, and non-aggregated PTLP samples.
- The produced PTLPs are suitable for sensitivity testing and structural analysis.
Conclusions:
- Optimized methods provide a reliable way to produce C. difficile PTLPs.
- These PTLPs represent a viable alternative for CDI treatment.
- Further studies can utilize these purified PTLPs for detailed analysis and therapeutic development.
